Related Experiment Video
Updated: May 14, 2025
Author Spotlight: THP-1 Macrophage Response to LPS/ATP — Unveiling the Pyroptosis, Apoptosis, and Necroptosis Spectrum
Published on: May 3, 2024
NLRP3 inflammasome inhibits mitophagy during the progression of temporal lobe epilepsy
Mengqian Wu1, Cong Yu1, Fuli Wen2
1Department of Neurology, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fuzhou, 350001, China.
Abstract:
Epilepsy is a neurological disorder involving mitochondrial dysfunction and neuroinflammation. This study examines the relationship between NLRP3 inflammasome activation and mitophagy in the temporal lobe epilepsy, which has not been reported before. A pilocarpine-induced epileptic rat model was used to assess seizure activity and neuronal loss. Pyroptosis markers (NLRP3, cleaved Gasdermin D, IL-1β/IL-18), and autophagy/mitophagy activity (LC3B-II/I, BNIP3, TOMM20/LC3B colocalization) were analyzed via immunofluorescence, Western blot, and transmission electron microscopy. NLRP3 inhibitors and anti-IL-1β antibodies were administered to evaluate therapeutic effects. Epileptic rats exhibited progressive neuronal loss and seizure aggravation, correlating with NLRP3 inflammasome activation and pyroptosis. While general autophagy was upregulated, mitophagy was selectively impaired in the hippocampus. NLRP3 activation promoted IL-1β release, which suppressed mitophagy via PPTC7 upregulation. NLRP3 activation inhibitor (MCC950) and anti-IL-1β treatment restored mitophagy and reduced seizures. NLRP3 inflammasome-driven pyroptosis exacerbates epilepsy by impairing mitophagy activity via IL-1β/PPTC7. Targeted NLRP3 inhibition mitigates this cascade, offering a promising strategy for refractory epilepsy.
Insights
Epilepsy involves neuroinflammation and mitochondrial issues. Targeting NLRP3 inflammasome activation and restoring mitophagy shows promise for treating refractory epilepsy by reducing seizures and neuronal loss.
Area of Science:
- Neuroscience
- Immunology
- Cell Biology
Background:
- Epilepsy is a neurological disorder linked to mitochondrial dysfunction and neuroinflammation.
- NLRP3 inflammasome activation and its role in epilepsy, particularly concerning mitophagy, remain under-investigated.
Purpose of the Study:
- To investigate the relationship between NLRP3 inflammasome activation and mitophagy in temporal lobe epilepsy.
- To explore the therapeutic potential of targeting the NLRP3 inflammasome pathway in epilepsy.
Main Methods:
- Utilized a pilocarpine-induced epileptic rat model.
- Assessed seizure activity, neuronal loss, pyroptosis markers (NLRP3, cleaved Gasdermin D, IL-1β/IL-18), and autophagy/mitophagy markers (LC3B-II/I, BNIP3, TOMM20/LC3B colocalization) via immunofluorescence, Western blot, and transmission electron microscopy.
- Administered NLRP3 inhibitors and anti-IL-1β antibodies to evaluate therapeutic effects.
Main Results:
- Epileptic rats showed progressive neuronal loss and aggravated seizures, associated with NLRP3 inflammasome activation and pyroptosis.
- General autophagy was upregulated, but mitophagy was selectively impaired in the hippocampus.
- NLRP3 activation led to IL-1β release, suppressing mitophagy via PPTC7 upregulation.
- MCC950 (NLRP3 inhibitor) and anti-IL-1β treatment restored mitophagy and reduced seizure activity.
Conclusions:
- NLRP3 inflammasome-driven pyroptosis exacerbates epilepsy by impairing mitophagy through the IL-1β/PPTC7 pathway.
- Targeted NLRP3 inhibition represents a potential therapeutic strategy for refractory epilepsy.
